A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer: Presentation of safety data

Objective: There is a strong rationale for using immune checkpoint inhibitors (ICI) in locally advanced cervical cancer (LACC), particularly in combination with SOC chemoRT (CRT). The question of sequential versus concurrent use has not been addressed prospectively. Moreover, the safety of combining ICI with pelvic CRT has not been established. The current study was designed in part to evaluate the safety of the combination.